BOLT Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Bolt Biotherapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerBOLT

Market Cap10.3M

Cash RunwayRunway 6-12 months

Next Catalyst2027-05

Public Research Snapshot

Bolt Biotherapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for BDC-1001 in Metastatic Breast Cancer | HER2-positive Breast Cancer (Phase 2) using Antibody.

Pipeline

Asset	Indication	Modality	Stage	Public Note
BDC-4182	Gastric Cancer Adenocarcinoma Metastatic \| Gastroesophageal Adenocarcinoma	Antibody	Preclinical	Public pipeline row
Preclinical	n/a	n/a	Preclinical	Public pipeline row
BDC-4182 Opportunity	n/a	n/a	n/a	Public pipeline row
BDC-1001	Metastatic Breast Cancer \| HER2-positive Breast Cancer	Antibody	Phase 2	Public pipeline row
BDC-3042	n/a	Antibody	Phase 1	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2027-05	BDC-4182	Low

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT05954143	Phase 2	TERMINATED	11	2024-09-20
NCT04278144	Phase 1 \| Phase 2	TERMINATED	175	2024-12-10
NCT06052852	Phase 1	TERMINATED	17	2025-08-01
NCT06921837	Phase 1 \| Phase 2	RECRUITING	122	2027-05

Scientific Context

literature_publication | CMC Regulatory Considerations for Antibody-Drug Conjugates.
asset_name | BDC-1001
clinical_stage | Phase 2
clinical_stage | Phase 1 | Phase 2
clinical_stage | Phase 2

Want the full BOLT research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.